Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_999_Библиотеки_им_академика_М_И_Перельмана
.pdf
7 Elective Surgery forPatients withSubstance Use Disorder or Recent Substance Misuse
https://t.me/med1917
6. Global status report on alcohol and health 2018. World Health Organization; 2018. https://www.
who.int/substance_abuse/publications/global_alcohol_report/en/. Accessed 20 Apr 2023.
7. 2021 National Survey on Drug Use and Health. Table5.6A—Alcohol use disorder in past year:
among people aged 12 or older; by age group and demographic characteristics, numbers in
thousands, 2021. SAMHSA, Center for Behavioral Health Statistics and Quality. 2021. https://
www.samhsa.gov/data/sites/default/files/reports/rpt39441/NSDUHDetailedTabs2021/
NSDUHDetailedTabs2021/NSDUHDetTabsSect5pe2021.htm#tab5.6a.
8. Reinert DF, Allen JP. The alcohol use disorders identication test: an update of research
ndings. Alcohol Clin Exp Res. 2007;31:185–99.
.00295.x.
9. Wolfson B, Freed B. Inuence of alcohol on anesthetic requirements and acute toxicity.
Anesth Analg. 1980;59(11):826–30.
10. Tønnesen H.Alcohol abuse and postoperative morbidity. Dan Med Bull. 2003;50(2):139–60.
11. Rolfzen ML, Mikulich-Gilbertson SK, Natvig C, Carrico JA, Lobato RL, Krause M, Bartels
K.Association between alcohol use disorder and hospital outcomes in colectomy patients- a
retrospective cohort study. J Clin Anesth. 2022 Jun;78:110674.
12. White CA, Quinones A, Tang JE, Butler LR, Duey AH, Kim JS, Cho SK, Cagle PJ.A national
analysis of the effect alcohol use disorder has on short-term complications and readmissions
following total shoulder arthroplasty. J Orthop. 2022 Oct;27(35):13–7.
13. Ponce BA, Oladeji LO, Raley JA, Menendez ME.Analysis of perioperative morbidity and
mortality in shoulder arthroplasty patients with preexisting alcohol use disorders. J Shoulder
Elb Surg. 2015;24(2):167–73.
14. HCUP.Most common operations during inpatient stays. Agency for healthcare research and
quality. 2021.
15. Gaddini GW, Turner RT, Grant KA, Iwaniec UT.Alcohol: a simple nutrient with complex
actions on bone in the adult skeleton. Alcohol Clin Exp Res. 2016;40(4):657–71.
16. Tønnesen H, Rosenberg J, Nielsen HJ, et al. Effect of preoperative abstinence on
poor postoperative outcome in alcohol misusers: randomised controlled trial. BMJ.
1999;318(7194):1311–6.
17. Egholm JW, Pedersen B, Møller AM, Adami J, Juhl CB, Tønnesen H. Perioperative alcohol cessation intervention for postoperative complications. Cochrane Database Syst Rev.
2018;11(11):CD008343. https://doi.org/10.1002/14651858.CD008343.pub3.
18. Tobacco. World Health Organization; 2022. https://www.who.int/news- room/fact- sheets/
detail/tobacco.
19. Park Lee E, Ren C, Cooper M, Cornelius M, Jamal A, Cullen KA.Tobacco product use among
middle and high school students—United States, 2022. Morb Mortal Wkly Rep. 2022;71:45.
20. Cornelius ME, Loretan CG, Wang TW, Jamal A, Homa DM.Tobacco product use among
adults— United States, 2020. MMWR Morb Mortal Wkly Rep. 2022;71:397–405.
21. Feinstein MM, Schlosberg I, Israilov S, Sison M, Katz D.A survey assessing the vaping habits of patients undergoing surgery. Respir Care. 2022;67(10):1332–4. https://doi.org/10.4187/
respcare.09830.
22. Schwilk B, Bothner U, Schraag S, Georgieff M.Perioperative respiratory events in smokers and
nonsmokers undergoing general anaesthesia. Acta Anaesthesiol Scand. 1997;41(3):348–55.
23. Møller AM, Maaløe R, Pedersen T.Postoperative intensive care admittance: the role of tobacco
smoking. Acta Anaesthesiol Scand. 2001;45(3):345–8.
6576.2001.045003345.x.
24. Sharma A, Deeb AP, Iannuzzi JC, Rickles AS, Monson JR, Fleming FJ.Tobacco smoking and
postoperative outcomes after colorectal surgery. Ann Surg. 2013;258(2):296–300. https://doi.
org/10.1097/SLA.0b013e3182708cc5.
25. Kapadia BH, Issa K, Pivec R, Bonutti PM, Mont MA.Tobacco use may be associated with
increased revision and complication rates following total hip arthroplasty. J Arthroplast.
2014;29(4):777–80. https://doi.org/10.1016/j.arth.2013.08.023.
26. Frick WG, Seals RR Jr. Smoking and wound healing: a review. Tex Dent J. 1994;111(6):21–3.
https://www.hcup- us.ahrq.gov/.
https://doi.org/10.1111/j.1530- 0277.2006
https://doi.org/10.1034/j.1399-
121

122
https://t.me/med1917
27. Krueger J, Rohrich R.Clearing the smoke: the scientic rationale for tobacco abstention with
plastic surgery. Plast Reconstr Surg. 2001;108:1063.
28. Chun LF, Moazed F, Calfee CS, Matthay MA, Gotts JE.Pulmonary toxicity of e-cigarettes.
Am J Physiol Lung Cell Mol Physiol. 2017;313(2):L193–206. https://doi.org/10.1152/
ajplung.00071.2017.
29. Roberts M, Davies M. Dangers of using e-cigarettes before anaesthesia.
BMJ. 2014;348:g1310.
30. Bieganowski T, Singh V, Kugelman DN, Rozell JC, Schwarzkopf R, Lajam CM. Vaping
trends and outcomes in primary Total joint arthroplasty patients: an analysis of 21,341
patients. J Am Acad Orthop Surg Glob Res Rev. 2023;7(1):e22.00110.
31. Rau AS, Reinikovaite V, Schmidt EP, Taraseviciene-Stewart L, Deleyiannis FW.Electronic
cigarettes are as toxic to skin ap survival as tobacco cigarettes. Ann Plast Surg.
2017;79(1):86–91. https://doi.org/10.1097/SAP.0000000000000998.
32. Møller AM, Villebro N, Pedersen T, Tønnesen H.Effect of preoperative smoking intervention
on postoperative complications: a randomised clinical trial. Lancet. 2002;359(9301):114–7.
33. Shi Y, Warner DO.Surgery as a teachable moment for smoking cessation. Anesthesiology.
2010;112:102–7.
34. Rao BM, Moylan DD, Sochacki KR, Kollmorgen RC, Atwal L, Ellis TJ.Mandatory nicotine
cessation for elective orthopedic hip procedures results in reduction in postoperative nicotine
use. Cureus. 2020;12(12):e12158.
35. Mason DP, Subramanian S, Nowicki ER, etal. Impact of smoking cessation before resection
of lung cancer: a Society of Thoracic Surgeons general thoracic surgery database study. Ann
Thorac Surg. 2009;88(2):362–71. https://doi.org/10.1016/j.athoracsur.2009.04.035.
36. Mills E, Eyawo O, Lockhart I, Kelly S, Wu P, Ebbert JO.Smoking cessation reduces postoperative complications: a systematic review and meta-analysis. Am J Med. 2011;124(2):144–154.
e8. https://doi.org/10.1016/j.amjmed.2010.09.013.
37. Warner MA, Diverti MR, Tinker JH, etal. Preoperative cessation of smoking and pulmonary
complications in coronary artery bypass patients. Anesthesiology. 1984;60:380–3.
38. Bryson EO, Frost EA. The perioperative implications of tobacco, marijuana, and other
inhaled toxins. Int Anesthesiol Clin. 2011 Winter;49(1):103–18.
39. Selvaggi G, Spagnolo AG, Elander A.A review of illicit psychoactive drug use in elective
surgery patients: detection, effects, and policy. Int J Surg. 2017 Dec;48:160–5.
40. Weaver MF, Hopper JA, Gunderson EW.Designer drugs 2015: assessment and management.
Addict Sci Clin Pract. 2015;10:8.
41. Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm.
2010;67(16):1344–50.
42. Goel A, McGuinness B, Jivraj NK, Wijeysundera DN, Mittleman MA, Bateman BT, Clarke
H, Kotra LP, Ladha KS.Cannabis use disorder and perioperative outcomes in major elective
surgeries: a retrospective cohort analysis. Anesthesiology. 2020 Apr;132(4):625–35.
43. Huson HB, Granados TM, Rasko Y.Surgical considerations of marijuana use in elective procedures. Heliyon. 2018;4(9):e00779.
44. Guarisco JL, Cheney ML, LeJeune FE Jr, Reed HT.Isolated uvulitis secondary to marijuana
use. Laryngoscope. 1988;98(12):1309–12.
45. Mallat A, Roberson J, Brock-Utne JG.Preoperative marijuana inhalation--an airway concern.
Can J Anaesth. 1996;43(7):691–3.
46. White SM.Cannabis abuse and laryngospasm. Anaesthesia. 2002;57(6):622–3.
47. Tashkin DP, Coulson AH, Clark VA, et al. Respiratory symptoms and lung function in
habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of
tobacco alone, and nonsmokers. Am Rev Respir Dis. 1987;135(1):209–16.
48. Benson M, Bentley AM.Lung disease induced by drug addiction. Thorax. 1995;50:1125–7.
49. Hernandez M, Birnbach DJ, Van Zundert AA.Anesthetic management of the illicit- substanceusing patient. Curr Opin Anaesthesiol. 2005;18(3):315–24.
T. Scott and E. O. Bryson

7 Elective Surgery forPatients withSubstance Use Disorder or Recent Substance Misuse
https://t.me/med1917
50. Kaar SJ, Ferris J, Waldron J, Devaney M, Ramsey J, Winstock AR.Up: the rise of nitrous
oxide abuse. An international survey of contemporary nitrous oxide use. J Psychopharmacol.
2016;30(4):395–401. https://doi.org/10.1177/0269881116632375.
51. Garakani A, Jaffe RJ, Savla D, et al. Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature. Am J Addict.
2016;25(5):358–69. https://doi.org/10.1111/ajad.12372.
52. Kong JT, Schmiesing C.Concealed mothball abuse prior to anesthesia: mothballs, inhalants,
and their management. Acta Anaesthesiol Scand. 2005;49:113–6.
53. Kurtzman TL, Otsuka KN, Wahl RA.Inhalant abuse by adolescents. J Adolesc Health.
2001;28:170–80.
54. Therapeutic Drug Management and Toxicology Division: Nitrous Oxide. American
Association for Clinical Chemistry. https://www.aacc.org/community/divisions/
tdm- and- toxicology/toxin- library/nitrous- oxide.
55. Broussard LA. The role of the laboratory in detecting inhalant abuse. Clin Lab Sci.
2000;13:205–9.
56. Caris MG, Kuipers RS, Kiestra BE, etal. Nitrous oxide abuse leading to extreme homocysteine
levels and thrombosis in young adults: a case series. J Thromb Haemost. 2023;21(2):276–83.
https://doi.org/10.1016/j.jtha.2022.10.002.
57. den Uil SH, Vermeulen EGJ, Metz R, Rijbroek A, de Vries M.Aortic arch thrombus caused by
nitrous oxide abuse. J Vasc Surg Cases Innov Tech. 2018;4(2):80–2. https://doi.org/10.1016/j.
jvscit.2018.01.001.
58. Vollenbrock SE, Fokkema TM, Leijdekkers VJ, Vahl AC, Konings R, van Nieuwenhuizen
RC.Nitrous oxide abuse associated with severe thromboembolic complications. Eur J Vasc
Endovasc Surg. 2021;62(4):656–7. https://doi.org/10.1016/j.ejvs.2021.05.041.
59. Bass M.Sudden snifng death. JAMA. 1970;212:2075–9.
60. Campdesuner V, Teklie Y, Alkayali T, Pierce D, George J.Nitrous oxide-induced vitamin
B12 deciency resulting in myelopathy. Cureus. 2020;12(7):e9088. https://doi.org/10.7759/
cureus.9088.
61. Centers for Disease Control and Prevention. Wide-ranging online data for epidemiologic
research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2021. http://
wonder.cdc.gov
62. Key substance use and mental health indicators in the United States: Results from the 2019
National Survey on Drug Use and Health (HHS Publication No. PEP20–07–01-001, NSDUH
Series H-55). Center for Behavioral Health Statistics and Quality, Substance Abuse and
Mental Health Services Administration; 2020. https://www.samhsa.gov/data/.
63. Henshaw DS, Turner JD, Khanna AK. Opioid abuse and perioperative care: a new
medical disease. Curr Opin Anaesthesiol. 2022;35(3):401–8. https://doi.org/10.1097/
ACO.0000000000001121.
64. Shah RM, Hirji SA, Percy E, Landino S, Yazdchi F, Bellavia A, Pelletier MP, Shekar PS,
Kaneko T.Cardiac surgery in patients with opioid use disorder: an analysis of 1.7 million
surgeries. Ann Thorac Surg. 2020 Apr;109(4):1194–201.
65. Arora S, Bronkema C, Majdalany SE, Corsi N, Rakic I, Piontkowski A, Sood A, Davis MJ,
Modonutti D, Novara G, Rogers CG, Abdollah F.Impact of preexisting opioid dependence on
morbidity, length of stay, and inpatient cost of urological oncological surgery. World J Urol.
2023;41(4):1025–31.
66. Menendez ME, Ring D, Bateman BT. Preoperative Opioid Misuse is Associated With
Increased Morbidity and Mortality After Elective Orthopaedic Surgery. Clin Orthop Relat
Res. 2015;473(7):2402–12.
67. Lavender TW, McCarron B.Acute infections in intravenous drug users. Clin Med (Lond).
2013 Oct;13(5):511–3.
68. Fisher RB, Johnson QL, Reeves-Viets JL, Pain management mini-series. Part II. Chronic
opioid drug therapy: implications for perioperative anesthesia and pain management. Mo
Med. 2013;110(3):231–5.
https://doi.org/10.1007/s00345- 023- 04306- 1.
https://doi.org/10.1007/s11999- 015- 4173- 5.
https://doi.org/10.7861/clinmedicine.13- 5- 511.
123

124
https://t.me/med1917
69. Thomas DA, Boominathan P, Goswami J, etal. Perioperative management of patients with
addiction to opioid and nonopioid medications. Cur Pain Headache Rep. 2018;22:52.
70. Shah S, Kapoor S, Durkin B.Analgesic management of acute pain in opioid tolerant patients:
a growing challenge. Curr Opin Anaesthesiol. 2015;28:398–402.
71. Schwenk S, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional
Anesthesia and Pain Medicine, the American Academy of Pain medicine, and the American
Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):456–66.
72. McNicol ED, Ferguson MC, Hudcova J. Patient controlled opioid analgesia versus nonpatient controlled opioid analgesia for postoperative pain. Cochrane Database Syst Rev.
2015;2015(6):CD003348.
73. Harrison TK, Kornfeld H, Aggarwal AK, Lembke A. Perioperative considerations for the
patient with opioid use disorder on buprenorphine, methadone or naltrexone maintenance
therapy. Anesthesiol Clin. 2018;36:345–59.
74. Exclusivity Data. Orange book: approved drug products with therapeutic equivalence evaluations. 37th ed. US Dept. of Health and Human services, Food and Drug Administration,
Center for Drug Evaluation and Research, Ofce of Pharmaceutical Science, Ofce of
Generic Drugs; 2017.
75. Kornfeld H, Manfredi L. Effectiveness of full agonist opioids in patients stabilized on
buprenorphine undergoing major surgery: a case series. Am J Ther. 2010;17:523–8.
76. Childers JW, Arnold RM. Treatment of pain in patients taking buprenorphine for opioid
addiction #221. J Palliat Med. 2012;15:613–4.
77. Anderson TA, Quaye AN, Ward N, etal. To stop or not to stop, that is the question-acute
pain management for the patient on chronic buprenorphine. Anesth Analg. 2017;126:1180–6.
78. McCance-Katz EF, Sullivan LE, Nallani S.Drug interactions of clinical importance among
opioids, methadone and buprenorphine, and other frequently prescribed medications: a
review. Am J Addict. 2010;19:4–16.
79. Sudakin D.Naltrexone: not just for opioids anymore. J Med Toxicol. 2016;12(71–75):21.
80. Bryson EO.The perioperative management of patients maintained on medication used to
manage opioid addiction. Curr Opin Anesthesiol. 2014;27:359–64.
81. Sordo L, Bario G, Bravo MJ, etal. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
82. What is the scope of cocaine use in the United States? NIDA; 2023. https://nida.nih.gov/
publications/research- reports/cocaine/what- scope- cocaine- use- in- united- states. Accessed 9
May 2023.
83. Hill GE, Ogunnaike BO, Johnson ER.General anaesthesia for the cocaine abusing patient. Is
it safe? Br J Anaesth. 2006 Nov;97(5):654–7. https://doi.org/10.1093/bja/ael221.
84. O’Donnell J, Gladden RM, Mattson CL, Kariisa M.Notes from the eld: overdose deaths
with Carfentanil and other fentanyl analogs detected—10 states, July 2016-June 2017.
MMWR Morb Mortal Wkly Rep. 2018;67(27):767–8.
85. Brust JC. Neurologic complications of illicit drug abuse. Continuum (Minneap Minn).
2014;20(3 Neurology of Systemic Disease):642–56.
86. Levent A, Davelaar EJ.Illegal drug use and prospective memory: a systematic review. Drug
Alcohol Depend. 2019;204:107478.
87. Derlet RW, Rice P, Horowitz BZ, Lord RV. Amphetamine toxicity: experience with 127
cases. J Emerg Med. 1989;7(2):157–61.
88. Burday MJ, Martin SE.Cocaine-associated thrombocytopenia. Am J Med. 1991;91(6):656–60.
89. Vagts DA, Boklage C, Galli C.Intraoperative ventricular brillation in a patient with chronic
cocaine abuse—a case report [in German]. Anaesthesiol Reanim. 2004;29:19–24.
90. Ciriaco P, Rossetti F, Carretta A, Sant'Angelo M, Arrigoni G, Negri G.Spontaneous pneumothorax in cocaine users. QJM. 2019;112(7):519–22. https://doi.org/10.1093/qjmed/hcz070.
91. Paratz ED, Cunningham NJ, MacIsaac AI.The cardiac complications of methamphetamines.
Heart Lung Circ. 2016;25(4):325–32.
T. Scott and E. O. Bryson

7 Elective Surgery forPatients withSubstance Use Disorder or Recent Substance Misuse
https://t.me/med1917
92. Safdari KM, Converse C, Dong F, etal. Hemodynamic Effects of Methamphetamine and
General Anesthesia. Anesthesiol Res Pract. 2022;2022:7542311.
93. Moon TS, Pak TJ, Kim A, Gonzales MX, Volnov Y, Wright E, Vu KQ, Lu RD, Shari
A, Minhajuddin A, Chen JL, Fox PE, Gasanova I, Fox AA, Stewart J, Ogunnaike B. A
positive cocaine urine toxicology test and the effect on intraoperative hemodynamics
under general anesthesia. Anesth Analg. 2021;132(2):308–16. https://doi.org/10.1213/
ANE.0000000000004808.
94. Granite EL, Farber NJ, Adler P.Parameters for treatment of cocaine-positive patients. J Oral
Maxillofac Surg. 2007;65(10):1984–9.
95. José FJ, Francina F, Matilde E, Magí F, Marta T.Therapeutic use of LSD in psychiatry: a
systematic review of randomized-controlled clinical trials. Front Psychiatry. 2020;10:943.
96. Liester MB.A review of lysergic acid diethylamide (LSD) in the treatment of addictions:
historical perspectives and future prospects. Curr Drug Abuse Rev. 2014;7:146.
97. Bogenschutz MP, Johnson MW.Classic hallucinogens in the treatment of addictions. Prog
Neuro-Psychopharmacol Biol Psychiatry. 2016;64:250–8.
98. Kometer M, Schmidt A, Jancke L, Vollenweider FX.Activation of serotonin 2A receptors
underlies the psilocybin-induced effects on oscillations, N170 visual-evoked potentials, and
visual hallucinations. J Neurosci. 2013;33:10544–1.
99. Hwang KAJ, Saadabadi A. Lysergic Acid Diethylamide (LSD). In: StatPearls [internet].
Treasure Island (FL): StatPearls Publishing; 2023. ncbi.nlm.nih.gov/books/NBK482407/.
100. The growing threat of Xylazine and its mixture with illicit drugs. DEA Joint Intelligence
Report, 2022.
of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf.
www.dea.gov/sites/default/les/2022- 12/The%20Growing%20Threat%20
125

Chapter 8
https://t.me/med1917
Illicit Drugs andCandidates forEndoscopy
andSurgery
JohnP.Gallagher, PatrickA.Twohig, AgnesCrnic, andFedjaA.Rochling
Abbreviations
HIV Human immunodeciency virus
IDU Illicit drug use
THC Tetrahydrocannabinol
UDS Urine drug screen
Introduction
Scope oftheProblem
Illicit drug use (IDU) encompasses a broad spectrum of substances and patterns of
use, and it is a common occurrence in the healthcare system. Patients with IDU are
frequently encountered during preprocedural evaluation in outpatient and emergent
settings. IDU is projected to rise as drug legalization continues to expand [1, 2]. These
patients are at increased risk for complications from anesthesia and intraoperative
complications related to recent drug use. When encountering patients with IDU, providers must decide whether to cancel the procedure or proceed while managing
J. P. Gallagher
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
e-mail: john.gallagher@unmc.edu
P. A. Twohig (
Division of Gastroenterology and Hepatology, The University of Nebraska Medical Center,
Omaha, NE, USA
e-mail: frochling@unmc.edu
A. Crnic
Department of Anesthesiology and Pain Medicine, University of Ottawa, The Ottawa
Hospital, Ottawa, ON, Canada
e-mail: acrni047@uottawa.ca
Switzerland AG 2024
J. Faintuch, S. Faintuch (eds.), Recent Strategies in High Risk Surgery,
https://doi.org/10.1007/978-3-031-56270-9_8
*) · F. A. Rochling
127© The Author(s), under exclusive license to Springer Nature

128
https://t.me/med1917
potential complications. Careful consideration must be taken to prevent anesthetic
interactions with commonly used drugs, as it can be challenging to ascertain the
recency of use, the severity of intoxication, and the potential for interactions with
anesthesia. Procedural delays are associated with signicant negative impacts on both
patients and the healthcare system. They should not be used universally in patients
with positive UDS, especially those who may appear non-toxic at presentation [3].
Delays or cancelations in elective procedures can create a signicant burden to
both patients and the healthcare system. It results in increased costs, care delays,
and decreased trust in the medical community [4, 5]. In addition, IDU is associated
with socioeconomically disadvantaged populations with greater comorbidity and
limited healthcare utilization [5]. Procedural delays may risk further marginalizing
this population and preventing access to care. It is critical to examine each patient
individually to determine procedural candidacy.
J. P. Gallagher et al.
Current Practices
The management of elective procedures in cases with IDU varies signicantly
across institutions [1, 6, 7]. The absence of standardized guidelines often leads physicians to rely on individual practices and expert recommendations when dealing
with such cases, despite a clear desire by practitioners for additional guidance [1].
Current practice patterns often delay elective procedures by up to 7days since
the last use as determined by urine or serum testing [8]. The majority of established
guidelines for administering anesthesia to patients with IDU focus on emergency
cases and managing the effects of acute intoxication [9, 10]. In such cases, specic
measures are required to mitigate potential interactions with anesthetics. Patients
who undergo emergency surgery have been found to require higher levels of sedation and exhibit an association with increased perioperative morbidity. There is also
an association between patients presenting for emergency surgery and increased
rates of the human immunodeciency virus (HIV) and Syphilis, which can complicate perioperative care [11]. However, multiple studies have demonstrated comparable 30-day clinical outcomes to the general population for patients who test
positive for illicit drugs in urine drug screen (UDS) but are non-toxic [6, 12–14].
Most literature also examines cases with general anesthesia rather than the lighter
sedation used for endoscopy. Here we discuss the systemic effects of frequently
encountered illicit drugs and procedural management considerations.
Anesthetic Considerations
The impact of IDU depends on the type of sedation being used. In the United States,
most endoscopies are performed using conscious sedation [15–17]. Notably, endoscopic procedures use signicantly lower doses of anesthetics when compared to
general anesthesia, and it is unknown what degree of procedural risk exists in this
clinical setting [17].

8 Illicit Drugs andCandidates forEndoscopy andSurgery
https://t.me/med1917
129
Cannabis
Physiologic Effects andPharmacodynamics
Cannabis is the most used illicit drug in the United States. It targets the cannabinoid
receptors, CB1 and CB2, located throughout the body and acting as G-proteincoupled receptors [18, 19]. It is a psychoactive agent that can act as a depressant,
stimulant, or hallucinogen in different settings. It is available in various forms, but
delta-9 tetrahydrocannabinol (THC) is the most psychoactive compound. The
effects of acute intoxication are highly variable and related to dose, formulation,
route of ingestion, and frequency of use. Physiologic manifestations of acute intoxication may include hypertension, tachypnea, tachycardia, euphoria, increased appetite, and conjunctival injection (Table8.1). The onset of action for acute intoxication
is approximately 15min when inhaled and up to 1–2h when ingested [19]. Duration
is 3–4h when inhaled and up to 12h if ingested. It is highly lipid soluble and can
be detected on urine drug testing for up to 30days after use [20].
Table 8.1 Duration of Urine drug screen positivity and anesthetic complications associated with
commonly encountered drugs. All values included in the table serve as estimates for general use
(Adapted with permission from “Illicit drug use and endoscopy: when do we say no?”)
Anesthetic
Duration of intoxication
Drug
Marijuana Inhaled: Up to 4
Cocaine Intravenous: 0.5–1
Methamphetamines Indeterminate, ranges from
Heroin 0.5, up to 4–5 for active
Ecstasy Ingested: 4–6 48h Tachycardia,
Phencyclidine
(PCP)
(hours)
Ingested: Up to 12
Intranasal: 1–2
Inhaled: 0.5–1
Ingested: Indeterminate
4h to 48h with residual
psychologic changes
metabolites
(6-monoacetylmorphine)
Intravenous: 1–2
Intranasal: Indeterminate
Inhaled: 1–2
Ingestion: 1–3
May experience prolonged
intoxication with delayed
release from adipose tissue
Duration of urine
positivity
3–30days with
chronic use
1–8days in most
cases, up to 22days
reported with
high-dose, chronic
use (30g/d inhaled)
1–7days, longer in
chronic use
24–48h Respiratory depression,
>1week Pulmonary
complications with
acute toxicity
Airway irritability,
hypotension, increased
anesthetic requirements
Tachyarrhythmias,
bronchospasm,
hemodynamic
instability, agitation
Hemodynamic
instability, myocardial
ischemia,
tachyarrhythmias
hypotension, increased
sedation requirements
hypertension,
hyperthermia,
hyperglycemia
hypertension,
tachycardia, psychosis,
cerebral hemorrhage

130
https://t.me/med1917
J. P. Gallagher et al.
Procedural Considerations
Patients with coronary artery disease are at increased risk of coronary spasms,
which are associated with myocardial ischemia, as well as arrhythmias, including
atrial brillation and ventricular brillation [21, 22].
When inhaled, cannabis use is associated with an increased risk for reactive airway disease, bronchospasm, laryngospasm, vocal cord dysfunction, uvular inammation, and airway edema. These risks can result in signicant intraoperative
complications, including hypoxemia when undergoing airway manipulation and
intubation and a higher risk of obstruction with airway instrumentation [21]. There
is limited data regarding the duration of increased risk after smoke exposure, but it
appears to be highest within 1–2h of use [21, 23]. Lastly, patients should be treated
with the same precautions as tobacco users, as there has been a similar risk prole
demonstrated with chronic cannabis use. Additional associations include increased
risk for cerebrovascular events, psychosis, hypothermia, and venous thromboembolism [24].
Anesthetic Interactions
Patients using cannabis have been shown to have inconsistent responses to various
forms of anesthesia and a need for increased analgesia postoperatively. Patients with
chronic use note more refractory pain and may require increased doses of as-needed
pain medication postoperatively compared to controls [21, 24]. In addition, patients
require more anesthesia to achieve sedation for both general anesthesia, deep sedation, and conscious sedation [24–26]. Due to the potential for tachycardia with
acute intoxication, drugs with chronotropic stimulation should be avoided, including ketamine, pancuronium, and atropine [27].
Perioperative Recommendations
The American Society of Regional Anesthesia and Pain Medicine released a 2023
consensus guidelines statement addressing periprocedural management of cannabis
use [28]. These included universal screening for THC prior to surgery, postponing
elective procedures in patients with signs of acute intoxication by at least 2h, and
counseling cannabis users on potential negative effects on postoperative pain control. It was also recommended to counsel pregnant patients on the fetal/neonatal
risks of cannabis use. Preprocedural UDS was not recommended due to inconsistencies and the inability to predict recency of use.
Due to the risk of increased anesthesia requirements and risk for withdrawal,
patients should be counseled on abstaining from cannabis use for up to 7 days

Marijuana
8 Illicit Drugs andCandidates forEndoscopy andSurgery
https://t.me/med1917
131
Preoperative Considerations
Universal UDS screening
Counseling on negative effects
Cessation 7 days prior to procedure
Perioperative Risks
Reactive airway disease
Coronary spasm, arrhythmias
Hypotension, bradycardia
Increased anesthetic needs
Drugs to avoid: Ketamine, pancuronium, atropine
Postoperative Considerations
Increased pain tolerance
Fig. 8.1 Procedural guidance with recent Marijuana use. UDS Urine drug screen
Hypoxia
Procedural Timing
Acute intoxication: Delay by 2 hours
Chronic use: Proceed
prior to planned procedures. It is reasonable to delay cases in the setting of acute
intoxication by at least 2 h, but non-toxic patients with recent use should be
allowed to proceed with procedures on a case-by-case basis. Special considerations must be taken intraoperatively and with pain management in the postoperative setting to avoid adverse outcomes in this population. In emergent cases where
the surgery will occur in less than 1day, it is important to note that patients with
acute intoxication may require increased sedation and have variable hemodynamic
responses to anesthesia with an increased risk of hypotension and bradycardia at
high doses [9, 29]. In patients with chronic use, weaning or cessation is not recommended due to the risk of cannabis withdrawal and/or increased anxiety or pain
(Fig.8.1) [23].
Cocaine
Physiologic Effects andPharmacodynamics
Cocaine is a stimulant and can be used in multiple formulations, including inhalation, intranasal, intravenous, and less commonly ingestion. The onset of action is
rapid and less than 5min, and the duration is between 60min to 2h [30]. Cocaine
blocks catecholamine uptake in the central nervous system and peripheral tissues,
Соседние файлы в папке Библиотека им академика М.И. Перельмана
